NEW YORK, USA | March 24, 2026
Gilgamesh Pharma, a clinical-stage neuroscience company focused on next-generation neuropsychiatric therapeutics, has successfully closed an oversubscribed $60 million Series A financing, signaling strong investor confidence in its innovative pipeline and breakthrough approach to mental health treatment. The funding round, led by Satori Neuro with participation from prominent institutional investors including Prime Movers Lab, marks a major milestone in advancing novel chemical entities (NCEs) designed to transform treatment paradigms in psychiatric and neurological disorders.
Strong Investor Confidence and Strategic Growth
The $60 million Series A financing represents the company’s first formal capital raise following its strategic spinout after AbbVie’s acquisition of Gilgamesh Pharmaceuticals in 2025. The new entity retains a robust portfolio of assets not included in the acquisition, along with continued support from prior collaborations with AbbVie.
The proceeds from this financing will be utilized to accelerate clinical development programs, expand discovery capabilities, and strengthen proprietary platforms focused on neuropsychiatric innovation. This strong investor backing highlights growing market interest in precision neuroscience and next-generation psychiatric therapeutics, particularly those addressing significant unmet medical needs in mental health.
Advancing Breakthrough Pipeline in Neuropsychiatry
Advertisement
Gilgamesh Pharma’s pipeline is anchored by blixeprodil (GM-1020), a non-competitive NMDA receptor antagonist currently being developed for major depressive disorder (MDD). The candidate recently demonstrated statistically significant and clinically meaningful improvements in Phase 2 trials, positioning it for late-stage clinical development in 2026. Designed as an oral therapy with rapid onset and improved tolerability, blixeprodil aims to overcome limitations associated with existing treatments.
In parallel, the company is progressing GM-3009, a cardio-safe ibogaine analog, expected to enter Phase 1 clinical trials, further diversifying its therapeutic pipeline. These programs reflect a broader strategy of leveraging novel mechanisms of action and neuroplasticity-based approaches to deliver durable and transformative patient outcomes.
Expanding Innovation Through Strategic Collaboration
The company continues to build on its ongoing collaboration with AbbVie, focused on developing neuroplastogen therapeutics, a promising class of compounds designed to enhance neural plasticity and repair. This partnership, along with internal research programs advancing toward IND-enabling studies, underscores Gilgamesh Pharma’s commitment to scientific innovation and scalable drug discovery platforms.
By integrating cutting-edge neuroscience, medicinal chemistry, and translational research, the company aims to move beyond traditional symptom management toward disease-modifying therapies. The successful Series A financing will further enable the company to expand its pipeline, accelerate timelines, and bring novel therapies closer to commercialization.
With a strong financial foundation, validated clinical progress, and a differentiated pipeline targeting complex neuropsychiatric disorders, Gilgamesh Pharma is emerging as a key innovator poised to redefine the future of mental health treatment and deliver meaningful, long-lasting benefits for patients worldwide.
Source: Gilgamesh Pharma press release
